echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Regarding the safety of "levothyroxine", the Food and Drug Administration released the "Pharmacovigilance Alert"!

    Regarding the safety of "levothyroxine", the Food and Drug Administration released the "Pharmacovigilance Alert"!

    • Last Update: 2023-01-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Introduction: The combination of levothyroxine and ciprofloxacin has been reported to cause hypothyroidism
    .
    When both classes of drugs are included in the prescription, patients should be informed to use
    them at least 6 hours apart.



    On November 2, 2022, the Drug Evaluation Center of the National Medical Products Administration and the National Adverse Drug Reaction Monitoring Center released the 10th issue of "Pharmacovigilance Alert", covering 4 aspects of information
    , including "New Zealand Drug and Medical Device Safety Administration suggests potential interaction between levothyroxine and ciprofloxacin".


    1
    .
    Japan warns of the risk of severe gastritis with nivolumab and pembrolizumab.

    2.
    The New Zealand Medicines and Medical Device Safety Administration suggests the potential interaction
    of levothyroxine with ciprofloxacin.

    3.
    Canada suggests the potential risk
    of serious heart-related problems, blood clots, cancer and death from JAK inhibitors (tofacitinib, baricitinib, upatinib).

    4.
    The European Medicines Agency (EMA) recommends measures to reduce the risk of
    respiratory failure and sepsis when terlipressin-containing drugs are treated with hepatorenal syndrome.


    The New Zealand Medicines and Medical Device Safety Administration has suggested potential interactions with levothyroxine with ciprofloxacin

     

    In June 2022, the New Zealand Medicines and Medical Device Safety Administration (Medsafe) announced that it was updating product information for levothyroxine and ciprofloxacin to include information
    on the risk of hypothyroidism due to drug interactions between levothyroxine and ciprofloxacin.

     

    Levothyroxine is used to treat hypothyroidism
    .
    Ciprofloxacin is a fluoroquinolone antibiotic indicated for adult infections
    caused by ciprofloxacin-sensitive pathogens.

     

    The Adverse Effects Monitoring Centre (CARM) in New Zealand received a report of
    symptoms of hypothyroidism in patients treated with levothyroxine plus ciprofloxacin.
    Symptoms improved
    after discontinuation of ciprofloxacin and temporary escalation of levothyroxine.
    In addition, one case report identified in the literature search suggested this interaction
    .

     

    Combination of two drugs should be at least 6 hours apart: It is recommended that medical personnel instruct patients to use at least 6 hours between
    doses when the two drugs are combined.
    Patients should be informed of this potential interaction, of signs and symptoms of concern (e.
    g.
    , fatigue, lethargy, or feeling cold), and of any changes
    in thyroid function.


    Information source:

    [1] style="white-space: normal;">[2] style="white-space: normal;">

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.